Study of AUR112 for advanced lymphoma or CLL
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new oral medication called AUR112 for people with advanced lymphoma or CLL that has not responded to at least 2 prior treatments. The goal is to see if it is safe and how it works in the body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia (CLL), or Hodgkin disease that has come back or not responded to treatment.
- You have already tried at least 2 different standard treatments for your cancer.
- You are able to swallow pills.
- Your kidney and liver function are good enough for the study (your doctor will check with blood tests).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental oral drug called AUR108 for people with advanced lymphoma that has come back after at least two prior treatments. The goal is to see if the drug is safe and if it can help shrink or control the lymphoma.
This early-phase study tests whether AUR107 is safe and may help shrink or control advanced solid tumors that have come back or progressed. You may be considered if standard treatments no longer work and you meet specific blood, organ, and health requirements.
This trial tests a new drug, AWT020, for people with advanced cancer (solid tumors or lymphoma) that hasn't responded to other treatments. The goal is to see if it is safe and how well it works.
This early study tests a new medicine (JAB-2485) in adults with advanced solid tumors (cancers that have spread or grown locally). You may join to see if it can shrink tumors or control the disease when other treatments haven’t worked or weren’t tolerated.
This trial tests an experimental drug called LP-284 in people with certain advanced lymphomas or solid tumors that have not responded to standard treatments. The goal is to see if it is safe and works against these cancers.
This Phase 1/2 study tests AVM0703 in people ages 12+ with certain lymphoid cancers that have returned or not responded to treatment. It may help shrink the cancer or control it when other treatments have failed or are not possible.
Hear when a new Relapsed Advanced Lymphomas trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.